NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.
Search Results
27 Results
The aerobiology team develops aerosol animal models of disease caused by high-consequence pathogens. Using advanced inhalational technologies, this team provides high experimental reproducibility to ensure the best modeling possible. Aerosolization procedures are fine-tuned to achieve accurate and precise dosimetry.
Developing, characterizing, and refining animal models rely on sophisticated medical imaging equipment; aerosol capabilities; and virology, pathology, molecular biology, and immunology expertise.
The NIAID-funded Bioinformatics Resource Centers provide data-driven, production-level, sustainable computational platforms to enable sharing and access to data, portable computational tools, and standards that support interoperability for the infectious diseases research community.
The Clinical Studies Support Team (CSST) develops and fosters overseas relationships through continuous support of research studies and clinical trials involving pathogens of high consequence. When deployed, the team provides in-person training and assistance with assays, equipment, and project management.
The core services team provides cell culture, hematology, hemostasis, clinical chemistry, microbiology, and molecular virology support for infectious disease studies at the IRF-Frederick. The team has the ability to perform pre-screening assessment by having parallel setups of clinical analyzers in biosafety level 4 (BSL-4) and BSL-2.
The drug screening team tests and characterizes novel compounds, drugs, and antibodies against numerous viruses in multiple cell lines under a variety of conditions. Compounds are evaluated in cell-based assays for inhibition of viral replication and reduction of virus yields, plaques, or cytopathic effect.
The Early Phase Clinical Trial Units (EPCTUs) support the design, development, implementation, and conduct of Phase 0 to Phase 2 clinical trials, including proof-of-concept studies in healthy, special, and disease-specific populations, carried out in an expeditious and efficient manner, aided by bioanalysis when necessary, against viral, bacterial, parasitic, and fungal pathogens and
The electron microscopy (EM) laboratory team uses transmission electron microscopy (TEM), scanning electron microscopy (SEM), negative staining techniques and assays, immunogold labeling, quantitation of biological samples, and other specialized methods.
The immunology team interrogates immune responses against pathogens requiring maximum containment by use of a variety of capabilities.
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical specimens.
The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.
The pathology and histology teams work together to conduct morphologic assessments and molecular assays using in-life and postmortem samples attained during research studies that develop and use established animal models of high-consequence emerging human viruses.
This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo and complex human cell-based in vitro model preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.
The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.
Therapeutic Development Services - Interventional Agents program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious pathogens, including bacteria, viruses, parasites, fungi, and toxins. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.
The Vaccine and Treatment Evaluation Units (VTEUs), supported by the Division of Microbiology and Infectious Diseases (DMID) since the 1960s, provide a ready resource for the conduct of clinical trials to evaluate promising vaccines, treatments, and diagnostics for infectious diseases.
The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).